title: Acceptability of formulations and application methods for vaginal microbicides among drug-involved women: results of product trials in three cities.
abstract: OBJECTIVE
  Female-controlled methods of HIV prevention, such as vaginal microbicides, are urgently needed, particularly among drug-involved women. Acceptability research is critical to product development.
  
  
  OBJECTIVE
  To assess the acceptability of forms and application methods for future microbicides.
  
  
  METHODS
  Eighty-four drug-involved women were introduced in groups to three lubricant products, asked to try each for 3 weeks, and scheduled for individual follow-up interviews.
  
  
  RESULTS
  Participants and their partners felt positive about the products, and expressed willingness to use microbicides if they were shown to be effective against HIV. Women agreed on product characteristics that influenced their reactions (e.g. ease of insertion, degree of "messiness"), but often disagreed on whether their reactions to these characteristics were positive or negative.
  
  
  CONCLUSIONS
  Development of acceptable and effective HIV-prevention products depends on understanding the interaction between characteristics of the products and the characteristics and perceptions of women. Levels of sexual risk and acceptability factors based on drug-use patterns, race and ethnicity, culture, age, and types and attitudes of male partners suggest that a "one size fits all" approach will not win broad acceptance among drug-involved women.
authors.affiliation: Abt Associates Inc, Cambridge, Massachusetts 02138-1168, USA. ted_hammett@abtassoc.com
authors.forename: T M
authors.initials: TM
authors.lastname: Hammett
authors.forename: T H
authors.initials: TH
authors.lastname: Mason
authors.forename: C L
authors.initials: CL
authors.lastname: Joanis
authors.forename: S E
authors.initials: SE
authors.lastname: Foster
authors.forename: P
authors.initials: P
authors.lastname: Harmon
authors.forename: R R
authors.initials: RR
authors.lastname: Robles
authors.forename: H A
authors.initials: HA
authors.lastname: Finlinson
authors.forename: R
authors.initials: R
authors.lastname: Feudo
authors.forename: S
authors.initials: S
authors.lastname: Vining-Bethea
authors.forename: G
authors.initials: G
authors.lastname: Jeter
authors.forename: K H
authors.initials: KH
authors.lastname: Mayer
authors.forename: P
authors.initials: P
authors.lastname: Doherty-Iddings
authors.forename: G R
authors.initials: GR
authors.lastname: Seage
mesh_terms: D000282:Administration, Intravaginal; D000328:Adult; D000890:Anti-Infective Agents / Q000627:therapeutic use*; D004338:Drug Combinations; D005260:Female; D005500:Follow-Up Studies; D005990:Glycerol / Q000627:therapeutic use; D015658:HIV Infections / Q000517:prevention & control*; D006801:Humans; D008055:Lipids; D008153:Lubrication; D010342:Patient Acceptance of Health Care; D011092:Polyethylene Glycols / Q000627:therapeutic use; D012307:Risk Factors; D012749:Sexually Transmitted Diseases / Q000517:prevention & control*; D015819:Substance Abuse, Intravenous / Q000382:microbiology*; D014622:Vaginal Creams, Foams, and Jellies / Q000627:therapeutic use
chemical_list: D000890:Anti-Infective Agents; D004338:Drug Combinations; D008055:Lipids; C085472:Replens; D014622:Vaginal Creams, Foams, and Jellies; C052495:lubrin; D011092:Polyethylene Glycols; D005990:Glycerol